Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Innovative stem cell therapy shows promise in restoring insulin production for severe type 1 diabetes patients.

Pharmaceutical Executive recently spoke with RheumaGen CEO Richard Freed about his career and the work the biotech is doing ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

Diabetes Mellitus is a chronic metabolic disorder and is one of the leading chronic diseases worldwide. It is widely known for its impact on blood sugar levels and conditions related to the ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School ...

In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Researchers uncover how diabetic peripheral neuropathy weakens bones via disrupted cellular communication using mouse models ...